New drug could slash steroid use in rare hormone disorder

NCT ID NCT04490915

Ongoing Disease control Sponsor: Neurocrine Biosciences Source: ClinicalTrials.gov ↗

First seen May 21, 2026 · Last updated May 21, 2026

Summary

This study tests a new medicine called crinecerfont for adults with classic congenital adrenal hyperplasia (CAH), a genetic condition that disrupts hormone production. The goal is to see if the drug can safely reduce the high doses of steroids patients need to take daily. About 182 participants will receive either crinecerfont or a placebo for 24 weeks, followed by a year of open-label treatment where everyone gets the active drug.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Neurocrine Clinical Site

Los Angeles, California, 90027, United States
Neurocrine Clinical Site

San Diego, California, 92123, United States
Neurocrine Clinical Site

San Francisco, California, 94143, United States
Neurocrine Clinical Site

Aurora, Colorado, 80045, United States
Neurocrine Clinical Site

Atlanta, Georgia, 30329, United States
Neurocrine Clinical Site

Indianapolis, Indiana, 46202, United States
Neurocrine Clinical Site

Bethesda, Maryland, 20982, United States
Neurocrine Clinical Site

Boston, Massachusetts, 02115, United States
Neurocrine Clinical Site

Ann Arbor, Michigan, 48109, United States
Neurocrine Clinical Site

Minneapolis, Minnesota, 55454, United States
Neurocrine Clinical Site

Rochester, Minnesota, 55905, United States
Neurocrine Clinical Site

St Louis, Missouri, 63110, United States
Neurocrine Clinical Site

Great Neck, New York, 11021, United States
Neurocrine Clinical Site

New York, New York, 10029, United States
Neurocrine Clinical Site

Winston-Salem, North Carolina, 27157, United States
Neurocrine Clinical Site

Tulsa, Oklahoma, 74135, United States
Neurocrine Clinical Site

Philadelphia, Pennsylvania, 19104, United States
Neurocrine Clinical Site

Pittsburgh, Pennsylvania, 15224, United States
Neurocrine Clinical Site

Dallas, Texas, 75390, United States
Neurocrine Clinical Site

Seattle, Washington, 98105, United States
Neurocrine Clinical Site

Graz, 8036, Austria
Neurocrine Clinical Site

Vienna, 1090, Austria
Neurocrine Clinical Site

Brussels, 1070, Belgium
Neurocrine Clinical Site

Leuven, 3000, Belgium
Neurocrine Clinical Site

Sofia, 1431, Bulgaria
Neurocrine Clinical Site

Sofia, 1606, Bulgaria
Neurocrine Clinical Site

Halifax, Nova Scotia, B3H 2Y9, Canada
Neurocrine Clinical Site

Hradec Králové, 50005, Czechia
Neurocrine Clinical Site

Angers, 49933, France
Neurocrine Clinical Site

Grenoble, 38700, France
Neurocrine Clinical Site

Le Kremlin-Bicêtre, 94270, France
Neurocrine Clinical Site

Nantes, 44093, France
Neurocrine Clinical Site

Paris, 75651, France
Neurocrine Clinical Site

Paris, 75679, France
Neurocrine Clinical Site

Dresden, 01307, Germany
Neurocrine Clinical Site

Essen, 45147, Germany
Neurocrine Clinical Site

Frankfurt, 60590, Germany
Neurocrine Clinical Site

Leipzig, 04103, Germany
Neurocrine Clinical Site

Munich, 80336, Germany
Neurocrine Clinical Site

Athens, 106 76, Greece
Neurocrine Clinical Site

Athens, 115 27, Greece
Neurocrine Clinical Site

Athens, 11527, Greece
Neurocrine Clinical Site

Thessaloniki, 54642, Greece
Neurocrine Clinical Site

Afula, 1834111, Israel
Neurocrine Clinical Site

Beersheba, 8410101, Israel
Neurocrine Clinical Site

Petah Tikva, 4941480, Israel
Neurocrine Clinical Site

Tel Aviv, 64239, Israel
Neurocrine Clinical Site

Ancona, 60126, Italy
Neurocrine Clinical Site

Bologna, 40138, Italy
Neurocrine Clinical Site

Florence, 50139, Italy
Neurocrine Clinical Site

Messina, 98125, Italy
Neurocrine Clinical Site

Milan, 20132, Italy
Neurocrine Clinical Site

Milan, 20149, Italy
Neurocrine Clinical Site

Naples, 80131, Italy
Neurocrine Clinical Site

Padova, 35128, Italy
Neurocrine Clinical Site

Roma, 00161, Italy
Neurocrine Clinical Site

Leiden, 2333, Netherlands
Neurocrine Clinical Site

Krakow, 31-011, Poland
Neurocrine Clinical Site

Poznan, 60-355, Poland
Neurocrine Clinical Site

Warsaw, 01-809, Poland
Neurocrine Clinical Site

Porto, 4200-319, Portugal
Neurocrine Clinical Site

Belgrade, 11000, Serbia
Neurocrine Clinical Site

Madrid, 28034, Spain
Neurocrine Clinical Site

Seville, 41013, Spain
Neurocrine Clinical Site

Gothenburg, 41345, Sweden
Neurocrine Clinical Site

Stockholm, 17176, Sweden
Neurocrine Clinical Site

Cardiff, CF14 4HH, United Kingdom
Neurocrine Clinical Site

London, WC1B 5EH, United Kingdom
Neurocrine Clinical Site

Manchester, M20 4BX, United Kingdom
Neurocrine Clinical Site

Salford, M6 8HD, United Kingdom

Conditions

Explore the condition pages connected to this study.

CONGENITAL ADRENAL HYPERPLASIA